FINWIRES · TerminalLIVE
FINWIRES

$XNCR

6 stories mentioning XNCRUpdated 39d ago

Every FINWIRES story that references XNCR, newest first.

Wire

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 1.7%.The iShares Biotechnology ETF (IBB) was up 0.3%.In corporate news, Xencor (XNCR) shares rose nearly 11% after the company said it has reached a settlement agreement with AstraZeneca (AZN) subsidiary Alexion Pharma International to resolve a commercial dispute over US royalties on Ultomiris. AstraZeneca shares were down 1.2%.Eli Lilly (LLY) expanded its collaboration with Resilience to invest $750 million as part of its effort to boost US production of Lilly's KwikPen injectable device for diabetes and obesity medicines, Resilience said Thursday. Lilly shares were down 4.4%.Johnson & Johnson (JNJ) said it has entered into strategic agreements with Sail Biomedicines to advance the biotech's in vivo CAR-T therapy platform for immune-mediated diseases, including an equity investment and an exclusive option to buy Sail for $2.58 billion. Johnson & Johnson shares fell 3.8%.Bausch Health (BHC) shares surged 26% after it reported higher Q2 results and raised its 2026 revenue outlook.Regeneron Pharmaceuticals (REGN) shares were up 6.3% after it reported higher Q2 results.

$AZN$BHC$JNJ$LLY$REGN$XNCR
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 1.5%.The iShares Biotechnology ETF (IBB) was up 0.3%.In corporate news, Xencor (XNCR) shares rose 11% after the company said it has reached a settlement agreement with AstraZeneca (AZN) subsidiary Alexion Pharma International to resolve a commercial dispute over US royalties on Ultomiris. AstraZeneca shares were down 1%.

$AZN$XNCR
Wire

Xencor Shares Rise After Settlement Deal With Alexion

Xencor (XNCR) shares were up about 10% in Thursday trading after the company said it has reached a settlement agreement with Astrazeneca (AZN) subsidiary, Alexion Pharma International, to resolve a commercial dispute over US royalties on Ultomiris.Xencor said it will receive $105 million in two equal payments following the settlement, adding that Alexion will no longer have to pay royalties on US sales of the drug.The company said it expects to continue receiving royalties on sales outside the US.Xencor added that it expects to have sufficient cash resources to fund programs and operations through 2028.Price: $21.56, Change: $+2.03, Percent Change: +10.39%

$AZN$XNCR
Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GLP-1 drugs, as manufacturing constraints should limit generic market penetration while the company's next-generation therapies are expected to preserve its market leadership, UBS Securities said in a note. Lilly shares were up 0.7%.Intuitive Surgical (ISRG) shares fell nearly 14%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.1% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Xencor (XNCR) shares jumped about 13% after the firm said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology Congress in October.

$GSK$ISRG$LLY$XNCR
Sectors

Sector Update: Healthcare

Healthcare stocks were softer late Friday afternoon, with the NYSE Healthcare Index 0.1% lower and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%.The iShares Biotechnology ETF (IBB) was fractionally lower.In corporate news, Xencor (XNCR) shares jumped 11% after the firm said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology Congress in October.

$XNCR
Wire

Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise

Xencor (XNCR) said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology, or ESMO, Congress in October.The company said expansion cohorts are evaluating intravenous doses to support selection of a recommended dose for a planned phase 3 study in advanced clear cell renal cell carcinoma, which is expected to begin in 2027.Shares of Xencor were up 8.6% in Friday afternoon trading.Price: $16.24, Change: $+1.28, Percent Change: +8.56%

$XNCR

Track with the FINWIRES app suite

FolioX
FolioX
Track XNCR in your portfolio
WheelAI
WheelAI
Analyze XNCR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on XNCR